muk nine: tailoring treatment for patients high-risk ndmm
Published 4 years ago • 52 plays • Length 5:28Download video MP4
Download video MP3
Similar videos
-
4:08
muk nine b update: dara-cvrd induction plus dara-vrd consolidation for ultra-high risk ndmm and ppcl
-
1:02
tailoring therapy for patients with multiple myeloma to improve outcomes
-
3:25
muk nine b: optimum, paving the way to effectively treat newly diagnosed high-risk mm
-
2:25
master final analysis: quadruplet induction therapy, asct & mrd-adapted treatment cessation in ndmm
-
2:55
molecular therapy stratification for high-risk mm: muk nine b optimum
-
1:48
muk nine study: what about tolerability?
-
2:00
the development of anti-fibrotic agents for treating myelofibrosis
-
2:46
managing patients with high-risk myeloma
-
8:13
treatment strategies for high-risk mm
-
1:36
the future tailoring of mm treatment
-
2:26
optimum/muknine: the risk of early relapse in patients with ultra high-risk multiple myeloma
-
2:30
a new era of treatment for multiple myeloma
-
1:23
management of high-risk newly diagnosed mm
-
4:00
immunotherapies for the treatment of high-risk mm
-
3:43
mrd-guided treatment cessation in multiple myeloma
-
2:20
ultra high-risk myeloma
-
1:01
latest advances in myelofibrosis treatment
-
1:00
quadruplet induction therapy in newly diagnosed high-risk myeloma